Gene Therapy Challenges: Additional Treatments for SMA Patients Raise Questions on Value

The remarkable promise of gene therapies has brought new hope to patients with debilitating conditions, offering the potential to replace faulty genes and provide life-changing improvements. However, recent experiences with the gene therapy Zolgensma in patients with spinal muscular atrophy (SMA) have highlighted potential challenges and questions about the value of such high-cost treatments.

SMA, a rare inherited disorder that severely weakens muscle control and function, particularly impacts children, leaving them unable to walk, talk, or even breathe. Zolgensma, a groundbreaking therapy introduced by Novartis in 2019, aims to replace the genes necessary for muscle control. Priced at a staggering $2.25 million per treatment, Zolgensma was initially positioned as a potential cure for SMA.

However, the reality has proven more complex. Despite the high price and accelerated regulatory approvals, many patients receiving Zolgensma have required additional treatments to address lingering symptoms and shortcomings. Some patients have not experienced the hoped-for outcomes, raising concerns about the value proposition of such expensive gene therapies.

Novartis’ data indicates that while Zolgensma has brought significant improvements for many patients, almost a third of children in an ongoing study eventually required supplementary treatments. The case of Baby Ben Kutschke, who received Zolgensma, achieved some initial improvements but later plateaued, leading to the introduction of other drugs.

This experience raises questions about the long-term benefits and value of gene therapies that come with exorbitant price tags. The potential for patients to require additional treatments can cast doubts on the justification for these high costs, especially if the anticipated revolutionary impact does not materialize.

As gene therapies continue to evolve and come to market, stakeholders, including patients, healthcare providers, insurers, and policymakers, will need to navigate these complex dynamics. Balancing the potential for transformative outcomes with the financial realities and ensuring that patients receive appropriate and effective treatments will remain a challenge in the field of gene therapy.

Click on the following links for more news from the California Examiner:

Get ahead of the curve by accessing breaking news and insightful articles on – start exploring today!

Scroll to Top